The Business Times
business-time-50

Mirxes

Companies & Markets

US$14.8 million in prepayments to vendors behind Mirxes’ missed 2025 results deadline; independent probe set up

Mirxes specialises in miRNA technology, developing blood-based diagnostic tests for the early detection of cancer and other diseases.
Companies & Markets

Singapore biotech Mirxes misses 2025 results deadline as auditors probe vendor payments

The Hong Kong-listed company did not declare any dividend for the six-month period.
Companies & Markets

A*Star biotech spin-off Mirxes trims losses to US$28.4 million as top line grows

Mirxes says it expects its addition to the index will significantly increase the company’s visibility and trading liquidity.
Companies & Markets

Singapore-headquartered Mirxes to join Alibaba, Tencent on Hang Seng Composite Index

Mirxes intends to use about half of the net proceeds for research and development, regulatory filings and manufacturing and commercialisation of Gastroclear.
Global Enterprise

Singapore biotech firm Mirxes launches IPO in Hong Kong to raise HK$1 billion 

Mirxes is still considering a secondary listing in Singapore, says CEO Dr Zhou Lihan.
Startups

‘A fighting chance’: Mirxes on why it chose Hong Kong over Singapore for its IPO

Mirxes co-founder Zhou Lihan says the company hopes to tap Hong Kong and China's healthcare and biotech investor base.
Global Enterprise

Singapore biotech Mirxes files for Hong Kong IPO after raising US$50 million

Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More